CSTL Castle Biosciences
- 24.330
- +1.490+6.52%
- 23.500
- -0.830-3.41%
Castle Biosciences News
Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Castle Biosciences (CSTL)
Castle Biosciences Analyst Ratings
Scotiabank Maintains Sector Outperform on Castle Biosciences, Raises Price Target to $37
Castle Biosciences Analyst Ratings
Outperform Rating for Castle Biosciences Amid Strong Market Presence and Growth Prospects
Analysts Conflicted on These Healthcare Names: Castle Biosciences (CSTL), DENTSPLY SIRONA (XRAY) and Silk Road Medical (SILK)
Analysts Conflicted on These Healthcare Names: Immunocore Holdings (IMCR), Voyager Therapeutics (VYGR) and Castle Biosciences (CSTL)
Buy Rating Affirmed for Castle Biosciences on Strong Performance and Positive Outlook
Scotiabank Reaffirms Their Buy Rating on Castle Biosciences (CSTL)
Guggenheim Initiates Coverage On Castle Biosciences With Buy Rating, Announces Price Target of $25
Castle Biosciences Analyst Ratings
Scotiabank Sticks to Its Buy Rating for Castle Biosciences (CSTL)
Castle Biosciences: Exceeding Forecasts and Dominating Skin Cancer Diagnostics Market – An Optimistic Buy Rating
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Castle Biosciences (CSTL) and Kura Oncology (KURA)
Analysts Offer Insights on Healthcare Companies: Castle Biosciences (CSTL), Axonics Modulation Technologies (AXNX) and Apellis Pharmaceuticals (APLS)
Analysts Offer Insights on Healthcare Companies: Castle Biosciences (CSTL), Lonza Group Ltd (Six Swiss: CH:LONN) and GN Store Nord (GB:0K9P)
Keybanc Maintains Overweight on Castle Biosciences, Lowers Price Target to $25
Castle Biosciences Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Insmed (INSM), Castle Biosciences (CSTL)
BTIG Remains a Buy on Castle Biosciences (CSTL)
Analysis
Price Target
No Data
